Adaptive behavior in autism: Minimal clinically important differences on the Vineland?II / Christopher H. CHATHAM in Autism Research, 11-2 (February 2018)  

Public ISBD [article]  inAutism Research > 11-2 (February 2018) . - p.270-283 Titre : Adaptive behavior in autism: Minimal clinically important differences on the Vineland?II Type de document : Texte imprimé et/ou numérique Auteurs : Christopher H. CHATHAM, Auteur ; K. I. TAYLOR, Auteur ; Tony CHARMAN, Auteur ; X. Liogier D'ARDHUY, Auteur ; E. EULE, Auteur ; A. FEDELE, Auteur ; A. Y. HARDAN, Auteur ; E. LOTH, Auteur ; L. MURTAGH, Auteur ; M. del Valle RUBIDO, Auteur ; Antonia SAN JOSE CACERES, Auteur ; J. SEVIGNY, Auteur ; L. SIKICH, Auteur ; L. SNYDER, Auteur ; J. E. TILLMANN, Auteur ; Pamela VENTOLA, Auteur ; Karen WALTON-BOWEN, Auteur ; P. P. WANG, Auteur ; T. WILLGOSS, Auteur ; Federico BOLOGNANI, Auteur Année de publication : 2018 Article en page(s) : p.270-283 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Autism Spectrum Disorder (ASD) is associated with persistent impairments in adaptive abilities across multiple domains. These social, personal, and communicative impairments become increasingly pronounced with development, and are present regardless of IQ. The Vineland Adaptive Behavior Scales, Second Edition (Vineland?II) is the most commonly used instrument for quantifying these impairments, but minimal clinically important differences (MCIDs) on Vineland?II scores have not been rigorously established in ASD. We pooled data from several consortia/registries (EU?AIMS LEAP study, ABIDE?I, ABIDE?II, INFOR, Simons Simplex Collection and Autism Treatment Network [ATN]) and clinical investigations and trials (Stanford, Yale, Roche) resulting in a data set of over 9,000 individuals with ASD. Two approaches were used to estimate MCIDs: distribution?based methods and anchor?based methods. Distribution?based MCID [d?MCID] estimates included the standard error of the measurement, as well as one?fifth and one?half of the covariate?adjusted standard deviation (both cross?sectionally and longitudinally). Anchor?based MCID [a?MCID] estimates include the slope of linear regression of clinician ratings of severity on the Vineland?II score, the slope of linear regression of clinician ratings of longitudinal improvement category on Vineland?II change, the Vineland?II change score maximally differentiating clinical impressions of minimal versus no improvement, and equipercentile equating. Across strata, the Vineland?II Adaptive Behavior Composite standardized score MCID estimates range from 2.01 to 3.2 for distribution?based methods, and from 2.42 to 3.75 for sample?size?weighted anchor?based methods. Lower Vineland?II standardized score MCID estimates were observed for younger and more cognitively impaired populations. These MCID estimates enable users of Vineland?II to assess both the statistical and clinical significance of any observed change. Autism Res 2018, 11: 270–283. © 2017 International Society for Autism Research, Wiley Periodicals, Inc. Lay Summary The Vineland Adaptive Behavior Scales (2nd edition; Vineland?II) is the most widely used scale for assessing day?to?day “adaptive” skills. Yet, it is unknown how much Vineland?II scores must change for those changes to be regarded as clinically significant. We pooled data from over 9,000 individuals with ASD to show that changes of 2–3.75 points on the Vineland?II Composite score represent the “minimal clinically?important difference.” These estimates will help evaluate the benefits of potential new treatments for ASD. En ligne : https://doi.org/10.1002/aur.1874 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=334 [article] Adaptive behavior in autism: Minimal clinically important differences on the Vineland?II [Texte imprimé et/ou numérique] / Christopher H. CHATHAM, Auteur ; K. I. TAYLOR, Auteur ; Tony CHARMAN, Auteur ; X. Liogier D'ARDHUY, Auteur ; E. EULE, Auteur ; A. FEDELE, Auteur ; A. Y. HARDAN, Auteur ; E. LOTH, Auteur ; L. MURTAGH, Auteur ; M. del Valle RUBIDO, Auteur ; Antonia SAN JOSE CACERES, Auteur ; J. SEVIGNY, Auteur ; L. SIKICH, Auteur ; L. SNYDER, Auteur ; J. E. TILLMANN, Auteur ; Pamela VENTOLA, Auteur ; Karen WALTON-BOWEN, Auteur ; P. P. WANG, Auteur ; T. WILLGOSS, Auteur ; Federico BOLOGNANI, Auteur . - 2018 . - p.270-283. Langues : Anglais (eng) in Autism Research > 11-2 (February 2018) . - p.270-283 Index. décimale : PER Périodiques Résumé : Autism Spectrum Disorder (ASD) is associated with persistent impairments in adaptive abilities across multiple domains. These social, personal, and communicative impairments become increasingly pronounced with development, and are present regardless of IQ. The Vineland Adaptive Behavior Scales, Second Edition (Vineland?II) is the most commonly used instrument for quantifying these impairments, but minimal clinically important differences (MCIDs) on Vineland?II scores have not been rigorously established in ASD. We pooled data from several consortia/registries (EU?AIMS LEAP study, ABIDE?I, ABIDE?II, INFOR, Simons Simplex Collection and Autism Treatment Network [ATN]) and clinical investigations and trials (Stanford, Yale, Roche) resulting in a data set of over 9,000 individuals with ASD. Two approaches were used to estimate MCIDs: distribution?based methods and anchor?based methods. Distribution?based MCID [d?MCID] estimates included the standard error of the measurement, as well as one?fifth and one?half of the covariate?adjusted standard deviation (both cross?sectionally and longitudinally). Anchor?based MCID [a?MCID] estimates include the slope of linear regression of clinician ratings of severity on the Vineland?II score, the slope of linear regression of clinician ratings of longitudinal improvement category on Vineland?II change, the Vineland?II change score maximally differentiating clinical impressions of minimal versus no improvement, and equipercentile equating. Across strata, the Vineland?II Adaptive Behavior Composite standardized score MCID estimates range from 2.01 to 3.2 for distribution?based methods, and from 2.42 to 3.75 for sample?size?weighted anchor?based methods. Lower Vineland?II standardized score MCID estimates were observed for younger and more cognitively impaired populations. These MCID estimates enable users of Vineland?II to assess both the statistical and clinical significance of any observed change. Autism Res 2018, 11: 270–283. © 2017 International Society for Autism Research, Wiley Periodicals, Inc. Lay Summary The Vineland Adaptive Behavior Scales (2nd edition; Vineland?II) is the most widely used scale for assessing day?to?day “adaptive” skills. Yet, it is unknown how much Vineland?II scores must change for those changes to be regarded as clinically significant. We pooled data from over 9,000 individuals with ASD to show that changes of 2–3.75 points on the Vineland?II Composite score represent the “minimal clinically?important difference.” These estimates will help evaluate the benefits of potential new treatments for ASD. En ligne : https://doi.org/10.1002/aur.1874 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=334

Decreased Cortical Thickness in the Anterior Cingulate Cortex in Adults with Autism / C. LAIDI in Journal of Autism and Developmental Disorders, 49-4 (April 2019)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 49-4 (April 2019) . - p.1402-1409 Titre : Decreased Cortical Thickness in the Anterior Cingulate Cortex in Adults with Autism Type de document : Texte imprimé et/ou numérique Auteurs : C. LAIDI, Auteur ; J. BOISGONTIER, Auteur ; A. DE PIERREFEU, Auteur ; Edouard DUCHESNAY, Auteur ; S. HOTIER, Auteur ; M. A. D'ALBIS, Auteur ; R. DELORME, Auteur ; Federico BOLOGNANI, Auteur ; C. CZECH, Auteur ; C. BOUQUET, Auteur ; Anouck AMESTOY, Auteur ; J. PETIT, Auteur ; S. HOLIGA, Auteur ; J. DUKART, Auteur ; A. GAMAN, Auteur ; E. TOLEDANO, Auteur ; M. LY-LE MOAL, Auteur ; Isabelle SCHEID, Auteur ; M. LEBOYER, Auteur ; J. HOUENOU, Auteur Article en page(s) : p.1402-1409 Langues : Anglais (eng) Mots-clés : Adults  Anterior cingulate cortex  Autism  Mri Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a developmental disorder underdiagnosed in adults. To date, no consistent evidence of alterations in brain structure has been reported in adults with ASD and few studies were conducted at that age. We analyzed structural magnetic resonance imaging data from 167 high functioning adults with ASD and 195 controls. We ran our analyses on a discovery (n = 301) and a replication sample (n = 61). The right caudal anterior cingulate cortical thickness was significantly thinner in adults with ASD compared to controls in both the discovery and the replication sample. Our work underlines the relevance of studying the brain anatomy of an adult ASD population. En ligne : https://dx.doi.org/10.1007/s10803-018-3807-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=388 [article] Decreased Cortical Thickness in the Anterior Cingulate Cortex in Adults with Autism [Texte imprimé et/ou numérique] / C. LAIDI, Auteur ; J. BOISGONTIER, Auteur ; A. DE PIERREFEU, Auteur ; Edouard DUCHESNAY, Auteur ; S. HOTIER, Auteur ; M. A. D'ALBIS, Auteur ; R. DELORME, Auteur ; Federico BOLOGNANI, Auteur ; C. CZECH, Auteur ; C. BOUQUET, Auteur ; Anouck AMESTOY, Auteur ; J. PETIT, Auteur ; S. HOLIGA, Auteur ; J. DUKART, Auteur ; A. GAMAN, Auteur ; E. TOLEDANO, Auteur ; M. LY-LE MOAL, Auteur ; Isabelle SCHEID, Auteur ; M. LEBOYER, Auteur ; J. HOUENOU, Auteur . - p.1402-1409. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 49-4 (April 2019) . - p.1402-1409 Mots-clés : Adults  Anterior cingulate cortex  Autism  Mri Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a developmental disorder underdiagnosed in adults. To date, no consistent evidence of alterations in brain structure has been reported in adults with ASD and few studies were conducted at that age. We analyzed structural magnetic resonance imaging data from 167 high functioning adults with ASD and 195 controls. We ran our analyses on a discovery (n = 301) and a replication sample (n = 61). The right caudal anterior cingulate cortical thickness was significantly thinner in adults with ASD compared to controls in both the discovery and the replication sample. Our work underlines the relevance of studying the brain anatomy of an adult ASD population. En ligne : https://dx.doi.org/10.1007/s10803-018-3807-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=388

Development of a patient-centered conceptual model of the impact of living with autism spectrum disorder / F. MCDOUGALL in Autism, 22-8 (November 2018)  

Public ISBD [article]  inAutism > 22-8 (November 2018) . - p.953-969 Titre : Development of a patient-centered conceptual model of the impact of living with autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : F. MCDOUGALL, Auteur ; T. WILLGOSS, Auteur ; S. HWANG, Auteur ; Federico BOLOGNANI, Auteur ; L. MURTAGH, Auteur ; Evdokia ANAGNOSTOU, Auteur ; D. ROFAIL, Auteur Article en page(s) : p.953-969 Langues : Anglais (eng) Mots-clés : autism spectrum disorder  conceptual model  qualitative research Index. décimale : PER Périodiques Résumé : The aim of this study was to generate a patient-centered conceptual model of the impact of living with autism spectrum disorder, which can be used to support the selection of outcome measures for clinical trials. Following an initial literature review to identify preliminary concepts and inform an interview guide, in-depth face-to-face interviews were conducted with adolescents and adults with autism spectrum disorder (IQ 70) (n = 10), as well as parents of children, adolescents, and adults with autism spectrum disorder (IQ 70) (n = 26). Data were analyzed using established qualitative research methods. The resultant conceptual model contains three interrelated domains reflecting core symptoms of autism spectrum disorder (communication deficits, socialization deficits, and restrictive, repetitive patterns of behavior), three domains reflecting associated symptoms of autism spectrum disorder (physical, cognitive, and emotional/behavioral), and three domains representing the impacts of living with autism spectrum disorder (impacts on activities of daily living, school/work, and social life). Interview respondents also cited social communication deficits as priority targets for new treatments. The conceptual model provides a patient-centered perspective of relevant concepts of autism spectrum disorder from the perspectives of people with autism spectrum disorder and their parents and offers a valuable tool for identifying valid patient-centered outcome measures for future clinical trials. En ligne : http://dx.doi.org/10.1177/1362361317718987 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=370 [article] Development of a patient-centered conceptual model of the impact of living with autism spectrum disorder [Texte imprimé et/ou numérique] / F. MCDOUGALL, Auteur ; T. WILLGOSS, Auteur ; S. HWANG, Auteur ; Federico BOLOGNANI, Auteur ; L. MURTAGH, Auteur ; Evdokia ANAGNOSTOU, Auteur ; D. ROFAIL, Auteur . - p.953-969. Langues : Anglais (eng) in Autism > 22-8 (November 2018) . - p.953-969 Mots-clés : autism spectrum disorder  conceptual model  qualitative research Index. décimale : PER Périodiques Résumé : The aim of this study was to generate a patient-centered conceptual model of the impact of living with autism spectrum disorder, which can be used to support the selection of outcome measures for clinical trials. Following an initial literature review to identify preliminary concepts and inform an interview guide, in-depth face-to-face interviews were conducted with adolescents and adults with autism spectrum disorder (IQ 70) (n = 10), as well as parents of children, adolescents, and adults with autism spectrum disorder (IQ 70) (n = 26). Data were analyzed using established qualitative research methods. The resultant conceptual model contains three interrelated domains reflecting core symptoms of autism spectrum disorder (communication deficits, socialization deficits, and restrictive, repetitive patterns of behavior), three domains reflecting associated symptoms of autism spectrum disorder (physical, cognitive, and emotional/behavioral), and three domains representing the impacts of living with autism spectrum disorder (impacts on activities of daily living, school/work, and social life). Interview respondents also cited social communication deficits as priority targets for new treatments. The conceptual model provides a patient-centered perspective of relevant concepts of autism spectrum disorder from the perspectives of people with autism spectrum disorder and their parents and offers a valuable tool for identifying valid patient-centered outcome measures for future clinical trials. En ligne : http://dx.doi.org/10.1177/1362361317718987 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=370

Psychiatric Comorbidities and Psychotropic Medication Use in Autism: A Matched Cohort Study with ADHD and General Population Comparator Groups in the United Kingdom / R. HOUGHTON in Autism Research, 11-12 (December 2018)  

Public ISBD [article]  inAutism Research > 11-12 (December 2018) . - p.1690-1700 Titre : Psychiatric Comorbidities and Psychotropic Medication Use in Autism: A Matched Cohort Study with ADHD and General Population Comparator Groups in the United Kingdom Type de document : Texte imprimé et/ou numérique Auteurs : R. HOUGHTON, Auteur ; C. LIU, Auteur ; Federico BOLOGNANI, Auteur Article en page(s) : p.1690-1700 Langues : Anglais (eng) Mots-clés : United Kingdom  attention deficit hyperactivity disorder  autism spectrum disorder  electronic medical records  polypharmacy  psychiatric comorbidities  psychotropic medications Index. décimale : PER Périodiques Résumé : Psychiatric comorbidities and use of psychotropic medications are common among patients with autism spectrum disorder (ASD). However, most previous research used data from the United States (US) and few studies have compared medication use in ASD to control groups, making contextualization of results difficult. In the United Kingdom (UK), general practitioners play a key role in the management of ASD. We conducted a retrospective, cross-sectional study over calendar year 2015, using primary care data from the UK. We identified a prevalent cohort of ASD cases (n = 10,856) and matched control groups of (a) general population (n = 21,712) and (b) attention deficit hyperactivity disorder (ADHD; n = 7,058) on age, sex and region. We described psychiatric comorbidities, psychotropic medications, and healthcare utilization in all three cohorts. Within the ASD cohort, we used multivariable logistic regression models to explore associations between patient characteristics and the outcomes of: any psychotropic medication, polypharmacy, and number of primary care visits. We used conditional logistic regression to compare the ASD and control groups. Psychiatric comorbidities were recorded for 41.5% of ASD patients; 32.3% received psychotropic medication and 9.8% received polypharmacy. Increased age and all psychiatric comorbidities (except conduct disorder) were associated with treatment use. Males were less likely to receive a treatment than females [Odds ratio (OR) 0.74 (0.66-0.83)]. ASD patients were more likely to take psychotropic medications than the general population [OR 4.91 (4.46-5.40)], but less likely compared to ADHD patients [OR 0.40 (0.37-0.44)]. Overall, rates of medication use in the UK were lower than those previously reported in the US. Autism Research 2018, 11: 1690-1700. (c) 2018 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: We used electronic medical records from the UK, to describe the amount of psychiatric comorbidities, psychotropic medication use and healthcare resource use in ASD. Around one in three people with ASD were prescribed a psychotropic medication, which was more than the general population, but less than for those with ADHD. Increased age, psychiatric comorbidities and female gender were all independently associated with psychotropic medication use. Rates of medication use in the UK were lower than those previously reported in the US. En ligne : http://dx.doi.org/10.1002/aur.2040 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=372 [article] Psychiatric Comorbidities and Psychotropic Medication Use in Autism: A Matched Cohort Study with ADHD and General Population Comparator Groups in the United Kingdom [Texte imprimé et/ou numérique] / R. HOUGHTON, Auteur ; C. LIU, Auteur ; Federico BOLOGNANI, Auteur . - p.1690-1700. Langues : Anglais (eng) in Autism Research > 11-12 (December 2018) . - p.1690-1700 Mots-clés : United Kingdom  attention deficit hyperactivity disorder  autism spectrum disorder  electronic medical records  polypharmacy  psychiatric comorbidities  psychotropic medications Index. décimale : PER Périodiques Résumé : Psychiatric comorbidities and use of psychotropic medications are common among patients with autism spectrum disorder (ASD). However, most previous research used data from the United States (US) and few studies have compared medication use in ASD to control groups, making contextualization of results difficult. In the United Kingdom (UK), general practitioners play a key role in the management of ASD. We conducted a retrospective, cross-sectional study over calendar year 2015, using primary care data from the UK. We identified a prevalent cohort of ASD cases (n = 10,856) and matched control groups of (a) general population (n = 21,712) and (b) attention deficit hyperactivity disorder (ADHD; n = 7,058) on age, sex and region. We described psychiatric comorbidities, psychotropic medications, and healthcare utilization in all three cohorts. Within the ASD cohort, we used multivariable logistic regression models to explore associations between patient characteristics and the outcomes of: any psychotropic medication, polypharmacy, and number of primary care visits. We used conditional logistic regression to compare the ASD and control groups. Psychiatric comorbidities were recorded for 41.5% of ASD patients; 32.3% received psychotropic medication and 9.8% received polypharmacy. Increased age and all psychiatric comorbidities (except conduct disorder) were associated with treatment use. Males were less likely to receive a treatment than females [Odds ratio (OR) 0.74 (0.66-0.83)]. ASD patients were more likely to take psychotropic medications than the general population [OR 4.91 (4.46-5.40)], but less likely compared to ADHD patients [OR 0.40 (0.37-0.44)]. Overall, rates of medication use in the UK were lower than those previously reported in the US. Autism Research 2018, 11: 1690-1700. (c) 2018 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: We used electronic medical records from the UK, to describe the amount of psychiatric comorbidities, psychotropic medication use and healthcare resource use in ASD. Around one in three people with ASD were prescribed a psychotropic medication, which was more than the general population, but less than for those with ADHD. Increased age, psychiatric comorbidities and female gender were all independently associated with psychotropic medication use. Rates of medication use in the UK were lower than those previously reported in the US. En ligne : http://dx.doi.org/10.1002/aur.2040 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=372

Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States / Richard HOUGHTON in Autism Research, 10-12 (December 2017)  

Public ISBD [article]  inAutism Research > 10-12 (December 2017) . - p.2037-2047 Titre : Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States Type de document : Texte imprimé et/ou numérique Auteurs : Richard HOUGHTON, Auteur ; Rose C. ONG, Auteur ; Federico BOLOGNANI, Auteur Article en page(s) : p.2037-2047 Langues : Anglais (eng) Mots-clés : autism spectrum disorder  claims database  medicaid  psychiatric comorbidities  polypharmacy  psychotropic medications Index. décimale : PER Périodiques Résumé : This study investigated psychotropic medication usage in two large, cohorts of people with autism spectrum disorder (ASD) throughout the calendar year 2014. The cohorts referred to individuals with commercial (employer-sponsored) and Medicaid insurance in the United States. We aimed to understand prescribing patterns of such medications across a wide age-range and in the presence/absence of other clinical and non-clinical characteristics, including psychiatric comorbidities. We described the prevalence and length of prescriptions by age, psychiatric comorbidity and overall. We also fitted multivariable logistic regression models to describe the relationship between treatments and subject characteristics simultaneously. Eighty percent of the identified population was male, although gender did not impact the odds of receiving medication. Medication use was strongly associated with age, increasing most rapidly before adulthood; generally plateauing thereafter. All psychiatric comorbidities studied also individually increased the chances of medication use, with epilepsy and ADHD having the highest associations in both the commercial (OR?>?7) and Medicaid (OR around 12) cohorts. Those in non-capitated insurance plans, in foster care and white individuals also had increased odds of prescriptions. Overall, slightly more Medicaid enrollees received any psychotropic treatment (commercial: 64%, Medicaid: 69%). Nonetheless in both cohorts, a large proportion of individuals received treatment even without a diagnosis of any other psychiatric comorbidity (commercial: 31%, Medicaid: 33%). In summary, this report sheds new light on the latest patterns of psychiatric comorbidity profile and psycho-pharmacological treatment patterns in ASD Autism Res 2017, 10: 2037–2047. © 2017 International Society for Autism Research, Wiley Periodicals, Inc. Lay Summary this study identified a large number of children and adults in the US with autism spectrum disorder (autism) from employer-sponsored and government funded (Medicaid) health insurance data. Psychotropic medications were used by over two thirds of people, and four in ten people received two medications at the same time. The chances of receiving medication increased for individuals with other psychiatric conditions (e.g., ADHD), and also increased with age. En ligne : http://dx.doi.org/10.1002/aur.1848 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=323 [article] Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States [Texte imprimé et/ou numérique] / Richard HOUGHTON, Auteur ; Rose C. ONG, Auteur ; Federico BOLOGNANI, Auteur . - p.2037-2047. Langues : Anglais (eng) in Autism Research > 10-12 (December 2017) . - p.2037-2047 Mots-clés : autism spectrum disorder  claims database  medicaid  psychiatric comorbidities  polypharmacy  psychotropic medications Index. décimale : PER Périodiques Résumé : This study investigated psychotropic medication usage in two large, cohorts of people with autism spectrum disorder (ASD) throughout the calendar year 2014. The cohorts referred to individuals with commercial (employer-sponsored) and Medicaid insurance in the United States. We aimed to understand prescribing patterns of such medications across a wide age-range and in the presence/absence of other clinical and non-clinical characteristics, including psychiatric comorbidities. We described the prevalence and length of prescriptions by age, psychiatric comorbidity and overall. We also fitted multivariable logistic regression models to describe the relationship between treatments and subject characteristics simultaneously. Eighty percent of the identified population was male, although gender did not impact the odds of receiving medication. Medication use was strongly associated with age, increasing most rapidly before adulthood; generally plateauing thereafter. All psychiatric comorbidities studied also individually increased the chances of medication use, with epilepsy and ADHD having the highest associations in both the commercial (OR?>?7) and Medicaid (OR around 12) cohorts. Those in non-capitated insurance plans, in foster care and white individuals also had increased odds of prescriptions. Overall, slightly more Medicaid enrollees received any psychotropic treatment (commercial: 64%, Medicaid: 69%). Nonetheless in both cohorts, a large proportion of individuals received treatment even without a diagnosis of any other psychiatric comorbidity (commercial: 31%, Medicaid: 33%). In summary, this report sheds new light on the latest patterns of psychiatric comorbidity profile and psycho-pharmacological treatment patterns in ASD Autism Res 2017, 10: 2037–2047. © 2017 International Society for Autism Research, Wiley Periodicals, Inc. Lay Summary this study identified a large number of children and adults in the US with autism spectrum disorder (autism) from employer-sponsored and government funded (Medicaid) health insurance data. Psychotropic medications were used by over two thirds of people, and four in ten people received two medications at the same time. The chances of receiving medication increased for individuals with other psychiatric conditions (e.g., ADHD), and also increased with age. En ligne : http://dx.doi.org/10.1002/aur.1848 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=323

---

1 (1 - 5 / 5)